ArticleRegenerative medicine
From targeted drug delivery to tissue regeneration: the evolving role of nanoparticle therapies in liver disease.
Article in Regenerative medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Chronic liver disease (CLD) cases are rising globally, impacting people across all age groups. The broad spectrum of etiologies and the heterogeneous presentation of CLDs make it challenging to develop effective therapeutic interventions. Current treatments focus on eliminating the underlying cause (e.g. in infections), reducing inflammation or slowing or halting fibrosis progression. However, these treatments lack specificity and have limited ability to repair or regenerate the damaged tissue. Due to the liver's unique regenerative capability, it can repair tissue damage during early stages of CLD; however, this ability is severely compromised during late-stage CLD, necessitating novel treatments to promote tissue regeneration. Nanoparticle (NP)-based drug delivery systems offer a versatile platform that can address many of the challenges of current CLD treatments. Through cell-specific surface modifications and encapsulation of multiple therapeutics within a single system, NPs can be engineered to provide targeted, sequential delivery of therapeutics and growth-promoting agents to the damaged liver. They can also be used to track the treatment and tissue repair post-administration. This Special Report examines current treatment challenges in CLD, highlights NPs' potential to address these challenges and outlines future directions for their use in liver disease management and tissue regeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.